Loading organizations...
Emeryville, California-based 4D Molecular Therapeutics is a clinical-stage biotechnology company that develops targeted gene therapies for severe genetic diseases using customized adeno-associated virus vectors. The publicly traded firm utilizes a proprietary directed evolution platform to engineer treatments for conditions across ophthalmology, pulmonology, and cardiology, including wet age-related macular degeneration and cystic fibrosis. Operating with over 150 employees, the company went public on the NASDAQ in 2020 and maintains a market capitalization of approximately $1 billion to $2 billion as of early 2024. The organization has established strategic pharmaceutical partnerships with industry leaders like Pfizer and features notable life sciences executives on its board, including former Gilead Sciences CEO John Milligan. Its clinical pipeline recently advanced after receiving Fast Track Designation from the FDA for its aerosolized cystic fibrosis candidate. 4D Molecular Therapeutics was founded in 2013 by David Kirn and UC Berkeley professor David Schaffer.
4D Molecular Therapeutics has raised $168.0M across 3 funding rounds.
4D Molecular Therapeutics has raised $168.0M in total across 3 funding rounds.
4D Molecular Therapeutics has raised $168.0M across 3 funding rounds. Most recently, it raised $75.0M Series C in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 16, 2020 | $75M Series C | Viking Global Investors | Amzak Health, ArrowMark Partners, Berkeley Catalyst Fund, BVF Partners, Casdin Capital, Chiesi Ventures, Michael Boyle, Longevity Vision Fund, Mirae Asset, Octagon Capital, Perceptive Advisors, Quad Investment Management | Announced |
| Sep 5, 2018 | $90M Series B | Viking Global Investors | Tony YAO, Berkeley Catalyst Fund, BVF Partners, Chiesi Ventures, Cureduchenne Ventures, Janus Henderson Investors, Mirae Asset, Perceptive Advisors, Ridgeback Capital Investments | Announced |
| Sep 19, 2017 | $3M Venture Round | Cystic Fibrosis Foundation | — | Announced |
4D Molecular Therapeutics has raised $168.0M in total across 3 funding rounds.
4D Molecular Therapeutics's investors include Viking Global Investors, Amzak Health, ArrowMark Partners, Berkeley Catalyst Fund, BVF Partners, Casdin Capital, Chiesi Ventures, Michael Boyle, Longevity Vision Fund, Mirae Asset, Octagon Capital, Perceptive Advisors.
